135 related articles for article (PubMed ID: 9611054)
1. Expression of p53 protein in borderline epithelial ovarian tumors: a clinicopathologic study of 39 cases.
Darai E; Walker-Combrouze F; Mlika-Cabanne N; Feldmann G; Madelenat P; Scoazec JY
Eur J Gynaecol Oncol; 1998; 19(2):144-9. PubMed ID: 9611054
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
3. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
[TBL] [Abstract][Full Text] [Related]
4. Proliferative activity and p53 over-expression of ovarian epithelial tumors.
Kuwata T; Kitagawa M; Takemura T; Hirokawa K
Gen Diagn Pathol; 1995 Oct; 141(2):131-9. PubMed ID: 8548593
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors.
Klemi PJ; Takahashi S; Joensuu H; Kiilholma P; Narimatsu E; Mori M
Int J Gynecol Pathol; 1994 Jul; 13(3):228-33. PubMed ID: 7928055
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.
Ozer H; Yenicesu G; Arici S; Cetin M; Tuncer E; Cetin A
Diagn Pathol; 2012 Sep; 7():124. PubMed ID: 22995373
[TBL] [Abstract][Full Text] [Related]
7. [Serous and mucinous epithelial ovarian tumors--a clinicopathologic study of 116 cases].
Giurgea NL; Pitrop M; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):389-94. PubMed ID: 23077925
[TBL] [Abstract][Full Text] [Related]
8. Volume-corrected mitotic index and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors.
Miliaras D
Anal Quant Cytol Histol; 1999 Oct; 21(5):425-9. PubMed ID: 10560525
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
10. p53 expression in ovarian borderline tumors and stage I carcinomas.
Kupryjańczyk J; Bell DA; Yandell DW; Scully RE; Thor AD
Am J Clin Pathol; 1994 Nov; 102(5):671-6. PubMed ID: 7942635
[TBL] [Abstract][Full Text] [Related]
11. The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors.
Giurgea LN; Ungureanu C; Mihailovici MS
Rom J Morphol Embryol; 2012; 53(4):967-73. PubMed ID: 23303020
[TBL] [Abstract][Full Text] [Related]
12. Alteration of BRCA-1 tumor suppressor gene expression in serous and mucinous ovarian neoplasms in the benign-borderline-malignant pathway.
Yousif HMA; Mohammed RAA
Curr Probl Cancer; 2019 Aug; 43(4):377-385. PubMed ID: 30446260
[TBL] [Abstract][Full Text] [Related]
13. Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma.
Ye F; Li Y; Hu Y; Zhou C; Hu Y; Chen H
Int J Gynecol Cancer; 2010 Aug; 20(6):958-64. PubMed ID: 20683402
[TBL] [Abstract][Full Text] [Related]
14. [Expression of folate receptor alpha in ovarian epithelial tumors].
Shen DH; Xie JL; Zhang YL; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):747-51. PubMed ID: 21215165
[TBL] [Abstract][Full Text] [Related]
15. P53, bcl-2, and nm23 expressions in serous ovarian tumors: correlation with the clinical and histopathological parameters.
Arik D; Kulaçoğlu S
Turk Patoloji Derg; 2011 Jan; 27(1):38-45. PubMed ID: 21469425
[TBL] [Abstract][Full Text] [Related]
16. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
Kalogeraki A; Tamiolakis D; Matalliotaki C; Karvela-Kalogeraki I; Karvelas-Kalogerakis M; Segredakis J; Sinatkas V; Matalliotakis I
Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):454-60. PubMed ID: 26204652
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors.
Zagorianakou N; Stefanou D; Makrydimas G; Zagorianakou P; Briasoulis E; Karavasilis V; Pavlidis N; Agnantis NJ
Histol Histopathol; 2006 Apr; 21(4):341-7. PubMed ID: 16437378
[TBL] [Abstract][Full Text] [Related]
18. [Expression P53 protein and chromosome aberrations in benign tumors and ovarian carcinoma].
Kamiński K; Putowski L; Oleszczuk J
Ginekol Pol; 2003 Sep; 74(9):741-5. PubMed ID: 14674118
[TBL] [Abstract][Full Text] [Related]
19. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer.
Nielsen JS; Jakobsen E; Hølund B; Bertelsen K; Jakobsen A
Int J Gynecol Cancer; 2004; 14(6):1086-96. PubMed ID: 15571614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
